-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, QioHaWBNLCr/7B4SwO6GDhmRkfpzOdRVyEpVqIerKLUmKNKQOrgNReWvwc0gGeRJ eTUJDTkA9FMrztwobzWoIA== 0001193125-06-190909.txt : 20060914 0001193125-06-190909.hdr.sgml : 20060914 20060914163133 ACCESSION NUMBER: 0001193125-06-190909 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 5 CONFORMED PERIOD OF REPORT: 20060731 FILED AS OF DATE: 20060914 DATE AS OF CHANGE: 20060914 FILER: COMPANY DATA: COMPANY CONFORMED NAME: KEWAUNEE SCIENTIFIC CORP /DE/ CENTRAL INDEX KEY: 0000055529 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY APPARATUS & FURNITURE [3821] IRS NUMBER: 380715562 STATE OF INCORPORATION: DE FISCAL YEAR END: 0430 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-05286 FILM NUMBER: 061091022 BUSINESS ADDRESS: STREET 1: 2700 W FRONT ST CITY: STATESVILLE STATE: NC ZIP: 28677 BUSINESS PHONE: 7048737202 MAIL ADDRESS: STREET 1: P O BOX 1842 CITY: STATESVILLE STATE: NC ZIP: 28687-1842 FORMER COMPANY: FORMER CONFORMED NAME: KEWAUNEE SCIENTIFIC EQUIPMENT CORP /DE/ DATE OF NAME CHANGE: 19861216 FORMER COMPANY: FORMER CONFORMED NAME: KEWAUNEE MANUFACTURING CO DATE OF NAME CHANGE: 19680108 10-Q 1 d10q.htm FORM 10-Q Form 10-Q
Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


FORM 10-Q

 


 

x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended July 31, 2006

 

¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from              to             

Commission file number 0-5286

 


KEWAUNEE SCIENTIFIC CORPORATION

(Exact name of registrant as specified in its charter)

 


 

Delaware   38-0715562

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S.Employer

Identification No.)

 

2700 West Front Street

Statesville, North Carolina

  28677
(Address of principal executive offices)   (Zip Code)

(704) 873-7202

(Registrant’s telephone number, including area code)

 


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and larger accelerated filer in Rule 12b-2 of the Exchange Act.

Large accelerated filer  ¨    Accelerated filer  ¨    Non-accelerated filer  x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  ¨    No  x

As of July 5, 2006, the Registrant had outstanding 2,492,270 shares of Common Stock.

Pages: This report, excluding exhibits, contains 18 pages numbered sequentially from this cover page.

 



Table of Contents

KEWAUNEE SCIENTIFIC CORPORATION

INDEX TO FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED JULY 31, 2006

 

        

Page

Number

PART I. FINANCIAL INFORMATION   
Item 1.   Financial Statements   
  Consolidated Statements of Operations - Three months ended July 31, 2006 and 2005    3
  Consolidated Balance Sheets July 31, 2006 and April 30, 2006    4
  Consolidated Statements of Cash Flows - Three months ended July 31, 2006 and 2005    5
  Notes to Consolidated Financial Statements    6
Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations    10
  Review by Independent Registered Public Accounting Firm    14
  Report of Independent Registered Public Accounting Firm    15
Item 3.   Quantitative and Qualitative Disclosures About Market Risk    16
Item 4.   Controls and Procedures    16
PART II. OTHER INFORMATION   
Item 4.   Submission of Matters to a Vote of Security Holders    17
Item 6.   Exhibits    17
SIGNATURE    18

 

2


Table of Contents

Part 1. Financial Information

Item 1. Financial Statements

Kewaunee Scientific Corporation

Consolidated Statements of Operations

(Unaudited)

(in thousands, except per share data)

 

     Three months ended
July 31
 
     2006     2005  

Net sales

   $ 19,294     $ 20,308  

Costs of products sold

     16,166       16,922  
                

Gross profit

     3,128       3,386  

Other operating income

     0       884  

Operating expenses

     2,637       2,920  
                

Operating earnings

     491       1,350  

Other income (expense)

     18       (5 )

Interest expense

     (187 )     (87 )
                

Earnings before income taxes

     322       1,258  

Income tax expense

     78       457  
                

Earnings before minority interests

     244       801  

Minority interests in subsidiaries

     111       38  
                

Net earnings

   $ 133     $ 763  
                

Net earnings per share

    

Basic

   $ 0.05     $ 0.31  

Diluted

   $ 0.05     $ 0.31  

Weighted average number of common shares outstanding (in thousands)

    

Basic

     2,492       2,492  

Diluted

     2,493       2,492  

See accompanying notes to consolidated financial statements.

 

3


Table of Contents

Kewaunee Scientific Corporation

Consolidated Balance Sheets

(in thousands)

 

     July 31
2006
    April 30
2006
 
     (Unaudited)        

Assets

    

Current assets:

    

Cash and cash equivalents

   $ 2,087     $ 929  

Restricted cash

     400       399  

Receivables, less allowance

     19,114       23,199  

Inventories

     6,156       5,860  

Deferred income taxes

     378       378  

Prepaid expenses and other current assets

     920       633  
                

Total current assets

     29,055       31,398  

Property, plant and equipment, at cost

     35,867       35,421  

Accumulated depreciation

     (24,738 )     (24,258 )
                

Net property, plant and equipment

     11,129       11,163  

Prepaid pension cost

     4,999       4,898  

Other

     3,013       3,013  
                

Total other assets

     8,012       7,911  

Total Assets

   $ 48,196     $ 50,472  
                

Liabilities and Stockholders' Equity

    

Current liabilities:

    

Short-term borrowings

   $ 8,531     $ 8,216  

Current obligations under capital leases

     297       260  

Accounts payable

     6,526       9,074  

Employee compensation and amounts withheld

     874       1,297  

Deferred revenue

     587       535  

Other accrued expenses

     1,229       991  
                

Total current liabilities

     18,044       20,373  

Obligations under capital leases

     611       583  

Deferred income taxes

     247       247  

Accrued employee benefit plan costs

     2,905       2,905  

Minority interests is subsidiaries

     919       818  
                

Total liabilities

     22,726       24,926  

Stockholders' equity:

    

Common stock

     6,550       6,550  

Additional paid-in-capital

     144       144  

Retained earnings

     19,484       19,526  

Accumulated other comprehensive income

     79       113  

Common stock in treasury, at cost

     (787 )     (787 )
                

Total stockholders' equity

     25,470       25,546  
                

Total Liabilities and Stockholders' Equity

   $ 48,196     $ 50,472  
                

See accompanying notes to consolidated financial statements.

 

4


Table of Contents

Kewaunee Scientific Corporation

Consolidated Statements of Cash Flows

(Unaudited)

(in thousands )

 

     Three months ended
July 31
 
     2006     2005  

Cash flows from operating activities:

    

Net earnings

   $ 133     $ 763  

Adjustments to reconcile net earnings to net cash used in operating activities:

    

Depreciation

     486       472  

Provision for bad debts

     2       38  

Deferred income tax expense

     0       (18 )

Gain on sale of property held for sale

     0       (884 )

Decrease in prepaid income taxes

     11       94  

Decrease in receivables

     4,083       414  

Increase in inventories

     (296 )     (1,396 )

Increase in prepaid pension cost

     (101 )     (60 )

(Decrease) increase in accounts payable and other current liabilities

     (2,744 )     1,388  

Increase (decrease) in deferred revenue

     52       (4 )

Other, net

     (220 )     (529 )
                

Net cash provided by operating activities

     1,406       278  

Cash flows from investing activities:

    

Capital expenditures

     (322 )     (832 )

Proceeds from sale of property held for sale

     0       2,500  

(Increase) decrease in restricted cash

     (1 )     6  
                

Net cash (used in) provided by investing activities

     (323 )     1,674  

Cash flows from financing activities:

    

Decrease in bank overdraft

     0       (2,301 )

Increase in short-term borrowings

     315       1,260  

Payments on long-term debt

     0       (279 )

Payments on capital leases

     (65 )     (38 )

Dividends paid

     (175 )     (175 )

Proceeds from exercise of stock options (including tax benefit)

     0       2  
                

Net cash provided by (used in) financing activities

     75       (1,531 )
                

Increase in cash and cash equivalents

     1,158       421  

Cash and cash equivalents, beginning of period

     929       225  
                

Cash and cash equivalents, end of period

   $ 2,087     $ 646  
                

See accompanying notes to consolidated financial statements.

 

5


Table of Contents

Kewaunee Scientific Corporation

Notes to Consolidated Financial Statements

(unaudited)

A. Financial Information

The unaudited interim consolidated financial statements of Kewaunee Scientific Corporation (the “Company” or “Kewaunee”) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “Commission”). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, although the Company believes that the disclosures are adequate to make the information presented not misleading.

These interim consolidated financial statements should be read in conjunction with the financial statements and notes included in the Company’s 2006 Annual Report to Stockholders. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.

The preparation of the financial statements requires management to make certain estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates.

Certain prior period amounts have been reclassified to conform to current classifications. These reclassifications had no impact on the results of operations of the Company.

B. Inventories

Inventories consisted of the following (in thousands):

 

     July 31, 2006    April 30,2006

Finished products

   $ 2,465    $ 1,653

Work in process

     682      745

Raw materials

     3,009      3,462
             
   $ 6,156    $ 5,860
             

For interim reporting, LIFO inventories are computed based on year-to-date quantities and interim changes in price levels. Changes in quantities and price levels are reflected in the interim financial statements in the period in which they occur.

 

6


Table of Contents

C. Comprehensive Income

A reconciliation of net earnings and total comprehensive income for the three months ended July 31, 2006 and 2005 is as follows (in thousands):

 

     Three months ended
July 31, 2006
    Three months ended
July 31, 2005
 

Net earnings

   $ 133     $ 763  

Change in fair value of cash flow hedge, net of income tax

     -0-       1  

Change in cumulative foreign currency translation adjustments

     (34 )     (5 )
                

Total comprehensive income (loss)

   $ 99     $ 759  

The Company records derivatives on the balance sheet at fair value and establishes criteria for designation and effectiveness of hedging relationships. The nature of the Company’s business activities involves the management of various financial and market risks, including those related to changes in interest rates. The Company may from time-to-time employ derivative financial instruments, such as interest rate swap contracts, to mitigate or eliminate certain of those risks. The Company does not enter into derivative instruments for speculative purposes. There were no derivative instruments outstanding at July 31, 2006.

For the Company’s foreign subsidiaries, assets and liabilities are translated at exchange rates prevailing on the balance sheet date. Revenues and expenses are translated at weighted average exchange rates prevailing during the period and any resulting translation adjustments are reported separately in shareholders’ equity.

 

7


Table of Contents

D. Share-based Compensation

In recent fiscal years, through fiscal year 2003, the Company used stock options as its primary long-term incentive plan for officers. The Company has not granted any stock options since fiscal year 2003. Prior to May 1, 2006, the Company accounted for its share-based employee compensation under the measurement and recognition provisions of Accounting Principles Board (“APB”) Option No. 25, “Accounting for Stock Issues to Employees” and related Interpretations, as permitted by SFAS No. 123, “Accounting for Stock-Based Compensation.” In accordance with these guidelines, the Company did not record any share-based employee compensation expense for options granted under its option plans prior to May 1, 2006, as all options granted under these plans had exercise prices equal to the fair market value of the Company’s common shares on the date of grant.

Effective May 1, 2006, the Company adopted the fair value recognition provisions of SFAS No. 123(R) “Share-Based Payment,” using the modified prospective transition method. Under that transition method, compensation expense that the Company recognizes beginning on May 1, 2006 includes compensation expense for all share options granted prior to, but not yet vested as of May 1, 2006, based on the grant date fair value estimated in accordance with the original provisions of SFAS No. 123. Expected fiscal year 2007 share-based compensation expense determined in accordance with SFAS No. 123(R) is $2,298. Results for prior periods are not required, nor have they been restated, for the adoption of SFAS 123(R).

Share-based compensation expense for the three months ended July 31, 2006 was $574, as compared to proforma compensation expense of $3,000 for the three months ended July 31, 2005.

 

8


Table of Contents

E. Defined Pension Plans

The Company has non-contributory defined benefit pension plans covering substantially all salaried and hourly employees. Effective April 30, 2005, no further benefits will be earned under the plans and no additional participants will be added to the plans. No contributions were paid to the plans during the three months ended July 31, 2006, and the Company does not expect any contributions to be paid to the plans during the remainder of the current fiscal year.

Pension expense (income) consisted of the following (in thousands):

 

    

Three months ended

July 31, 2006

   

Three months ended

July 31, 2005

 

Service Cost

   $ -0-     $ -0-  

Interest Cost

     208       195  

Expected return on plan assets

     (347 )     (311 )

Amortization of prior service costs

     -0-       -0-  

Recognition of net loss

     38       60  
                

Net periodic pension cost (income)

   $ (101 )   $ (56 )

F. Credit Arrangements

In May 2006, the Company increased its bank revolving credit facility from $9 million to $10 million. Total outstanding advances under the credit facility were $8.5 million at July 31, 2006. The two-year term of the $9 million portion of the facility expires on December 31, 2006, unless extended, and the $1 million portion expires on October 27, 2006, unless extended. The Company expects to extend both portions of the credit facility prior to their expiration.

 

9


Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The Company’s 2006 Annual Report to Stockholders contains management’s discussion and analysis of financial condition and results of operations at and for the year ended April 30, 2006. The following discussion and analysis describes material changes in the Company’s financial condition since April 30, 2006. The analysis of results of operations compares the three months ended July 31, 2006 with the comparable periods of the prior fiscal year.

Results of Operations

Sales for the three months ended July 31, 2006 were $19,294,000, a decrease of 5% from sales of $20,308,000 in the same period last year. The order backlog at July 31, 2006 was $36.5 million, as compared to a backlog of $36.4 million at April 30, 2006 and $40.7 million at July 31, 2005.

The gross profit margin for the three months ended July 31, 2006 was 16.2% of sales, as compared to 16.7% of sales in the comparable quarter of the prior year. The gross profit margin decline was due to lower selling prices in the domestic laboratory furniture market, partially offset by increased selling margins on international sales and sales of technical furniture.

Operating expenses for the three months ended July 31, 2006 were $2.6 million, or 13.7% of sales, as compared to $2.9 million, or 14.4% of sales, in the comparable period of the prior year. Operating expenses as a percent of sales declined during the current quarter as compared to the comparable quarter of the prior year due to lower administrative, bad debt, and marketing expenses.

Operating earnings were $491,000 for the three months ended July 31, 2006. This compares to operating earnings of $1,350,000 for the comparable period of the prior year. Operating earnings for the prior year period included a gain of $884,000 from the sale of the Company’s Lockhart, Texas property.

Interest expense was $187,000 for the three months ended July 31, 2006, as compared to $87,000 for the same period of the prior year. The increase in interest expense for the current year period resulted from higher interest rates, and to a lesser extent, higher borrowing levels in the current year.

Other income was $18,000 in the three months ended July 31, 2006, as compared to other expense of $5,000 for the comparable period of the prior year.

 

10


Table of Contents

Income tax expense of $78,000 was recorded for the three months ended July 31, 2006, as compared to income tax expense of $457,000 recorded for the comparable period of the prior year. The effective tax rate was 24.1% for the three months ended July 31, 2006 and was 36.0% for the three months ended July 31, 2005. The effective tax rates for both periods differ from the statutory rate primarily due to lower income tax rates on income earned by foreign subsidiaries. The reduction in the effective tax rate for the current year period as compared to the prior year period resulted from an increase in the percentage of the Company’s earnings that were earned by the foreign subsidiaries.

Minority interests result from the Company’s two subsidiaries that are not 100% owned by the Company. Minority interests reduced net earnings by $111,000 for the three months ended July 31, 2006, as compared to a reduction of $38,000 for the comparable period of the prior year. The increase in minority interests in the current period was directly related to increased earnings of the two subsidiaries.

Net earnings were $133,000, or $0.05 per diluted share, for the three months ended July 31, 2006. This compares to net earnings of $763,000, or $.31 per diluted share, for the comparable period of the prior year.

Liquidity and Capital Resources

Historically, the Company’s principal sources of liquidity have been funds generated from operations, supplemented as needed by short-term borrowings under the Company’s revolving credit facility. Additionally, certain machinery and equipment are financed by non-cancelable operating leases or capital leases. The Company believes that these sources will be sufficient to support ongoing business requirements, including capital expenditures through the current fiscal year.

The Company had working capital of $11.0 million at July 31, 2006, unchanged from April 30, 2006. The ratio of current assets to current liabilities was 1.6-to-1 at July 31, 2006, as compared to 1.5-to-1 at April 30, 2006. During the quarter the Company increased its bank revolving credit facility from $9,000,000 to $10,000,000. At July 31, 2006, advances of $8,531,000 were outstanding under the credit facility.

 

11


Table of Contents

The Company’s operations provided cash of $1,406,000 during the three months ended July 31, 2006. Cash was provided primarily from operations and a decrease in accounts receivable, which was partially offset by cash used to decrease accounts payable and other current liabilities. The decrease in accounts receivable during the quarter was consistent with a decline in sales during the current year period as compared to the previous quarter ended April 30, 2006.

The Company’s operations provided cash of $278,000 during the three months ended July 31, 2005. Cash was provided primarily from an increase in accounts payable and other current liabilities which was substantially offset by cash requirements resulting from an increase in inventories.

During the three months ended July 31, 2006, net cash of $323,000 was used by investing activities, primarily for capital expenditures. This compares to the net cash of $1,674,000 for investing activities in the same period of the prior year, primarily from the proceeds of sales of the Company’s former plant site in Lockhart, Texas, reduced by $832,000 for capital expenditures.

The Company’s financing activities provided cash of $75,000 during the three months ended July 31, 2006. Cash provided included $315,000 received from short-term borrowings, which was substantially offset by cash dividends paid of $175,000 and payments on obligations of capital leases of $65,000. Financing activities used cash of $1,531,000 in the same period of the prior year, which included $2,301,000 to reduce bank overdrafts, $279,000 for scheduled repayments of long-term debt and $175,000 for cash dividends, which were partially offset by an increase in short term borrowings of $1,260,000.

Outlook for Remainder of Fiscal Year 2007

The Company’s ability to predict future demand for its products continues to be very limited given, among other general economic factors affecting the Company and its markets, the Company’s role as subcontractor or supplier to dealers of subcontractors. In addition to general economic factors affecting the Company and its markets, demand for the Company’s products is also dependent upon the number of laboratory construction projects planned and/or current progress in projects already under construction. The Company’s earnings are also impacted by increased costs of raw materials, including stainless steel, wood, and epoxy resin, and whether the Company is able to increase product prices to customers in amounts that correspond to such increases without materially and adversely affecting sales.

 

12


Table of Contents

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Certain statements in this report constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, economic, competitive, governmental, and technological factors affecting the Company’s operations, markets, products, services, and prices. The cautionary statements made pursuant to the Reform Act herein and elsewhere by the Company should not be construed as exhaustive or as any admission regarding the adequacy of disclosures made by the Company prior to the effective date of the Reform Act. The Company cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. In addition, readers are urged to consider statements that include the terms “believes”, “belief”, “expects”, “plans”, “objectives”, “anticipates”, “intends” or the like to be uncertain and forward-looking. Over time, the Company’s actual results, performance or achievements will likely differ from the anticipated results, performance or achievements that are expressed or implied by the Company’s forward-looking statements, and such difference might be significant and harmful to stockholders’ interest. Many important factors that could cause such a difference are described under the caption “Risk Factors,” in Item 1A of the Company’s 2006 Annual Report on Form 10-K.

 

13


Table of Contents

REVIEW BY INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

A review of the interim financial information included in this Quarterly Report on Form 10-Q each of for the three month periods ended July 31, 2006 and July 31, 2005 has been performed by Cherry, Bekaert & Holland, L.L.P., the Company’s independent auditors. Their report on the interim financial information follows.

 

14


Table of Contents

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders of

Kewaunee Scientific Corporation

Statesville, North Carolina

We have reviewed the accompanying consolidated balance sheets of Kewaunee Scientific Corporation and its subsidiaries (the “Company”) as of July 31, 2006, and the related consolidated statements of operations and of cash flows for the three-month periods ended July 31, 2006 and 2005. These interim financial statements are the responsibility of the Company’s management.

We conducted our review in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States), the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our review, we are not aware of any material modifications that should be made to the consolidated interim financial statements referred to above for them to be in conformity with accounting principles generally accepted in the United States of America.

We previously audited, in accordance with the Standards of the Public Accounting Oversight Board (United States), the consolidated balance sheet as of April 30, 2006, and the related statements of operations, of stockholder’s equity and of cash flows for the year then ended (not presented herein) and in our report dated June 26, 2006, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying consolidated balance sheet as of April 30, 2006 is fairly stated in all material respects in relation to the consolidated financial statement from which it has been derived.

Cherry, Bekaert & Holland, L.L.P.

Charlotte, North Carolina

September 11, 2006

 

15


Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There are no material changes to the disclosures made on this matter in the Company’s Annual Report on Form 10-K for the fiscal year ended April 30, 2006.

Item 4. Controls and Procedures

(a) Evaluation of disclosure controls and procedures

An evaluation was performed under the supervision and the participation of the company’s management, including the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of July 31, 2006. Based on that evaluation, the Company’s management, including the CEO and CFO, concluded that, as of July 31, 2006, the Company’s disclosure controls and procedures were adequate and effective and designed to ensure that all material information required to be filed in this quarterly report is made known to them by others within the Company and its subsidiaries.

(b) Changes in internal controls

There were no significant changes in the Company’s internal controls or in other factors that could significantly affect these controls subsequent to July 31, 2006. As no significant deficiencies or material weaknesses were found, no corrective actions were taken.

 

16


Table of Contents

PART II. OTHER INFORMATION

Item 4. Submission of Matters to a Vote of Security Holders

The Company’s Annual Meeting of Stockholders was held on August 23, 2006. Each of the nominees for Class II directors was re-elected for a three-year term. The votes cast for and withheld from each such director were as follows:

 

Director

       For    Withheld

John C. Campbell, Jr.

     2,035,900    122,213

James T. Rhind

     2,023,059    135,054

William A. Shumaker

     2,151,763    6,350

Item 6. Exhibits and Reports on Form 8-K

 

31.1   Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2   Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1   Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2   Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

17


Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  KEWAUNEE SCIENTIFIC CORPORATION
                              (Registrant)
Date: September 12, 2006   By  

/s/ D. Michael Parker

    D. Michael Parker
    Senior Vice President, Finance and
    Chief Financial Officer

 

18

EX-31.1 2 dex311.htm SECTION 302 CEO CERTIFICATION Section 302 CEO Certification

EXHIBIT 31.1

CERTIFICATIONS

I, William A. Shumaker, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Kewaunee Scientific Corporation;

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and we have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

b) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of period covered by this report based on such evaluation; and

c) disclosed in this quarterly report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;


5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: September 12, 2006  
 

/s/ William A. Shumaker

  William A. Shumaker
  President and Chief Executive Officer
EX-31.2 3 dex312.htm SECTION 302 CFO CERTIFICATION Section 302 CFO Certification

EXHIBIT 31.2

CERTIFICATIONS

I, D. Michael Parker, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Kewaunee Scientific Corporation;

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and we have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

b) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of period covered by this report based on such evaluation; and

c) disclosed in this quarterly report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;


5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: September 12, 2006  
 

/s/ D. Michael Parker

  D. Michael Parker
 

Senior Vice President, Finance and

Chief Financial Officer

EX-32.1 4 dex321.htm SECTION 906 CEO CERTIFICATION Section 906 CEO Certification

EXHIBIT 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Kewaunee Scientific Corporation (the “Company”) for the period ending July 31, 2006, I, William A. Shumaker, President and Chief Executive Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

  (1) such Form 10-Q of the Company for the period ended July 31, 2006, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2) the information contained in such Form 10-Q of the Company for the period ended July 31, 2006, fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: September 12, 2006  
 

/s/ William A. Shumaker

  William A. Shumaker
  President and Chief Executive Officer
EX-32.2 5 dex322.htm SECTION 906 CFO CERTIFICATION Section 906 CFO Certification

EXHIBIT 32.2

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Kewaunee Scientific Corporation (the “Company”) for the period ending July 31, 2006, I, D. Michael Parker, Senior Vice President, Finance and Chief Financial Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

  (1) such Form 10-Q of the Company for the period ended July 31, 2006, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2) the information contained in such Form 10-Q of the Company for the period ended July 31, 2006, fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: September 12, 2006  
 

/s/ D. Michael Parker

  D. Michael Parker
 

Senior Vice President, Finance and

Chief Financial Officer

-----END PRIVACY-ENHANCED MESSAGE-----